Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma

Dades bibliogràfiques
Autors principals:	Shrimanker, R, Pavord, I, Price, R, Bradford, E, Keene, O, Yancey, S
Format:	Conference item
Publicat:	American Thoracic Society 2018

Ítems similars

Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide and their combination in severe asthma: a post-hoc analysis
per: Shrimanker, R, et al.
Publicat: (2019)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
per: Gunsoy, N, et al.
Publicat: (2017)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
per: Steven W. Yancey, et al.
Publicat: (2019-09-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
per: Howell, I, et al.
Publicat: (2024)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
per: Bel, E, et al.
Publicat: (2014)

Mepolizumab treatment in patients with severe eosinophilic asthma.
per: Ortega, H, et al.
Publicat: (2014)

Glucocorticoids and mepolizumab in eosinophilic asthma.
per: Bel, E, et al.
Publicat: (2014)

Mepolizumab in refractory eosinophilic asthma.
per: Pavord, I, et al.
Publicat: (2010)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
per: Imran Howell, et al.
Publicat: (2024-07-01)

Mepolizumab for eosinophilic COPD
per: Sciurba, F, et al.
Publicat: (2018)

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
per: Price, D, et al.
Publicat: (2019)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
per: Yancey, S, et al.
Publicat: (2016)

Diagnostic possibility of the combination of exhaled nitric oxide and blood eosinophil count for eosinophilic asthma
per: Jiang-Hua Li, et al.
Publicat: (2021-08-01)

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
per: David B. Price, et al.
Publicat: (2019-08-01)

Mepolizumab, quality of life, and severe eosinophilic asthma.
per: Pavord, I
Publicat: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
per: Ortega, H, et al.
Publicat: (2016)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
per: Shrimanker, R, et al.
Publicat: (2017)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
per: Haldar, P, et al.
Publicat: (2009)

Biomarkers for severe eosinophilic asthma.
per: Yancey, S, et al.
Publicat: (2017)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
per: Moran, AM, et al.
Publicat: (2020)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
per: Ian D. Pavord, et al.
Publicat: (2022-05-01)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
per: Shrimanker, R, et al.
Publicat: (2017)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
per: Arian Ghassemian, et al.
Publicat: (2021-01-01)

The peripheral blood eosinophil count as a biomarker of eosinophilic airway inflammation in patients with asthma and COPD. Experience from a single centre
per: Shrimanker, R, et al.
Publicat: (2017)

Mepolizumab for eosinophilic chronic obstructive pulmonary disease
per: Pavord, I, et al.
Publicat: (2017)

Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma
per: Jie Gao, et al.
Publicat: (2018-05-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
per: Terufumi Shimoda, et al.
Publicat: (2017-07-01)

Does a composite score combining peripheral blood eosinophils (PBE) and exhaled nitric oxide (FeNO) accurately predict a sputum eosinophilia?
per: Connolly, CM, et al.
Publicat: (2017)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
per: Pavord, I, et al.
Publicat: (2012)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
per: Prazma CM, et al.
Publicat: (2021-06-01)

Both fractional exhaled nitric oxide and sputum eosinophil were associated with uncontrolled asthma
per: Gao J, et al.
Publicat: (2018-04-01)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
per: Menzella F, et al.
Publicat: (2016-06-01)

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
per: Pavord, I, et al.
Publicat: (2017)

Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis
per: Charlene M. Prazma, et al.
Publicat: (2019-05-01)

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
per: Chio Sakai, et al.
Publicat: (2024-07-01)

The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.
per: Berry, M, et al.
Publicat: (2005)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
per: Wechsler, M, et al.
Publicat: (2017)

Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis
per: Buendía, JA, et al.
Publicat: (2022)

Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis
per: Jefferson Antonio Buendía, et al.
Publicat: (2022-06-01)

Treatment Resistance in Severe Asthma Patients With a Combination of High Fraction of Exhaled Nitric Oxide and Low Blood Eosinophil Counts
per: Yuki Hoshino, et al.
Publicat: (2022-04-01)